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Objective: Some previous studies have shown that gingipains, trypsin-like proteases pro-
duced by Porphyromonas gingivalis, up-regulate human b defensin-2 (HBD-2) mRNA expres-
sion through protease-activated receptor-2 (PAR2) in gingival epithelial cells. This study
aimed at investigating salivary HBD-2 levels and crevicular PAR2 mRNA expression in
human chronic periodontitis and evaluating whether periodontal treatment affected this
process.
Methods: Salivary and gingival crevicular fluid (GCF) samples were collected from periodon-
tally healthy (control) and chronic periodontitis patients at baseline and 50 days after non-
surgical periodontal treatment. Salivary HBD-2, and GCF TNF-a levels were analysed by
ELISA, and PAR2 mRNA at the GCF was evaluated by RT-PCR.
Results: P. gingivalis was significantly ( p < 0.05) more prevalent in patients with chronic
periodontitis when compared to controls. This prevalence decreased after periodontal
therapy ( p < 0.0001). The control group showed statistically significant lower levels of
HBD-2, TNF-a, and PAR2 expression when compared to the chronic periodontitis group.
In addition, periodontal treatment significantly reduced PAR2 expression and HBD-2 levels
in chronic periodontitis patients ( p < 0.001).
Conclusions: Our results suggest that salivary HBD-2 levels and PAR2mRNA expression from
GCF are higher in subjects with chronic periodontitis than in healthy subjects, and that
periodontal treatment decreases both HBD-2 levels and PAR2 expression.
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Human b-defensins (HBDs) are small cationic peptides
produced throughout the body, mainly by epithelial cells,
that play an important role in the oral cavity as a first-line
defence against gram-negative and gram-positive bacteria, as
they are able to create pores into the bacterial membranes,
killing the bacteria. Epithelial cells in the oral cavity* Corresponding author. Tel.: +55 12 3625 4149; fax: +55 12 3632 4968.
E-mail address: alupe@terra.com.br (A.L. Pereira).
Abbreviations: PAR2, protease-activated receptor-2; HBD-2, human
gingival index; PD, probing depth; CAL, clinical attachament level.
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Open access under the Elsevier OA license.constitutively express HBDs: HBD-1, HBD-2, and HBD-3.1,2
However, in the presence of inflammation, a different
expression of these peptides might occur.2–5 Dommisch et
al.2 showed that in healthy gingival tissues there is a similar
expression among HBD-1 and -2 mRNA. In contrast,
the expression of HBD-2 is statistically higher than human
b defensin-1 in both gingivitis and chronic periodontitis
subjects. b defensin-2; GCF, gingival crevicular fluid; PI, plaque index; GI,
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expression of HBD-1 and -2 mRNA was significantly higher in
chronic periodontitis subjects than in the healthy control
group. In addition, in a study by Kuula et al.,5 HBD-2
expression was found to be lower in periodontally healthy
tissues than in inflamed periodontal and peri-implant tissues.
Taken together, these studies suggest a potentially important
role for defensins in the host response to infection by
periodontal pathogens.
The modulation of the b-defensins expression in the oral
cavity can be orchestrated by receptors present in the cell
membrane that recognize certain molecular patterns associ-
ated to periodontal pathogens, including Aggregatibacter
actinomycetemcomitans, Porphyromonas gingivalis, and Fusobac-
terium nucleatum. Previous in vitro studies6,7 have shown that
gingipains, trypsin-like proteases produced by P. gingivalis, up-
regulate HBD-2 mRNA expression through protease-activated
receptor-2 (PAR2) in gingival epithelial cells. PAR2 belongs to
the family of G-protein-coupled, seven-transmembrane-do-
main receptors. Its activation occurs through the proteolytic
cleavage of the N-terminal domain by serine proteinases such
as trypsin, mast cell tryptase, neutrophil proteinase 3, tissue
factor/factor VIIa/factor Xa, membrane-tethered serine pro-
teinase-1, and gingipains.8,9 A recent study by our group10
compared chronic periodontitis patients to healthy controls
and showed that PAR2 is up-regulated in this first group. We
also showed that the presence of P. gingivalis in the periodontal
pocket is associated with this upregulation of PAR2 gene
expression and that a higher pro-inflammatory profile is
related to advanced periodontal destruction.11 In the present
study, we hypothesized that HBD-2 levels as well as the
expression of PAR2 are elevated in the saliva of chronic
periodontitis subjects. As to assess this hypothesis, the
salivary HBD-2 levels and the PAR2 mRNA expression from
GCF were investigated in chronic periodontitis and in healthy
subjects. In addition we also evaluated whether periodontal
treatment may affect these levels.
2. Materials and methods
2.1. Patients
All subjects were between 20 and 69 years and in good overall
health. Patients who reported history of tobacco usage within
six months of screening; use of orthodontic appliances; need
for premedication with antibiotics for dental treatment;
usage of antibiotics, phenytoin, calcium antagonists, cyclo-
sporine, or anti-inflammatory drugs within one month of
initial appointment; history of any disease known to
compromise immune functions; pregnancy or lactation;
immunosuppressive chemotherapy, and/or periodontal
treatment within the last 6 months, were not included in
the present study.
The study protocol was approved by the Institutional
Committee on Research of the University of Taubate (protocol
#385/08) in accordance with the Helsinki Declaration of 1975,
as revised in 2000. All patients were instructed in the nature
and objectives of the study and signed a consent form agreeing
to their participation.2.2. Clinical examination
Subjects were clinically evaluated with regards to the
probing pocket depths, clinical attachment loss and bleeding
upon probing recorded at six sites per tooth (mesiobuccal,
buccal, distobuccal, mesiolingual, lingual, distolingual)
using a manual periodontal probe (PCPUNC 15 – Hu-Friedy,
Chicago, IL, USA). Patients were then divided in two groups:
control (i), formed by those showing healthy sites with
probing depths of 3 mm, no attachment loss, no bleeding
on probing, or no signs of inflammation (10 subjects); and
chronic periodontitis (ii), formed by patients with at least
four teeth with one or more sites with probing depth  4 mm
and clinical attachment loss  3 mm, and bleeding on
probing. For each patient in the chronic periodontitis group
the periodontal site showing the deepest probing depth in
each oral quadrant was selected for the collection of
microbial and GCF samples.
2.3. Periodontal therapy
After the clinical evaluation, bacterial and saliva samples were
taken. Each subject received oral hygiene instructions and a
standard kit for mechanical supragingival plaque control. The
kit contained fluoride dentifrice, a regular toothbrush,
interdental toothbrushes, and dental floss. Subjects in the
healthy group were instructed about personal daily oral
hygiene care. Periodontitis subjects underwent scaling and
root planning under local anaesthesia, in a total of four clinical
visits.
Clinical data, microbial, crevicular fluid and salivary
samples were taken from the same sites at baseline and 50
days after initial therapy.
2.4. Microbial sampling and P. gingivalis analysis
The periodontal sites selected were isolated and the supragin-
gival plaque was carefully removed. One fine paper point
(number 30 – Tanari – Tanariman Industrial Ltd., Manacapuru,
Brazil) was inserted into the gingival sulcus/periodontal pocket
and left in place for 10 s. Samples collected were stored in 1 mL
of reduced Ringer’s solution (0.9 g sodium chloride, 0.042 g
potassium chloride, 0.025 g calcium chloride, 100 mL distilled
water) at 80 8C. Bacterial suspensions were thawed, centri-
fuged at 12,000  g for 1 min. The presence of P. gingivalis was
assessed by polymerase chain reaction (PCR) using specific
primers: sense 50AGGCAGCTTGCCATACTGCGG30, and anti-
sense: 50-ACTGTTAGCAACTACCGATGT-30 (product size:
404 bp) under standard conditions. DNA was extracted using
PureLink1 Genomic DNA Kit (Invitrogen, Carlsbad, CA, USA).
PCR was performed in a Mastercycler Gradient thermocycler
(Eppendorf, Hamburg, Germany) as follows: one cycle 94 8C for
5 min, 35 cycles 94 8C for 30 s, 57 8C for 30 s, 72 8C for 1 min, and a
final extension of 72 8C for 5 min.
After electrophoresis in 1.5% agarose gel, DNA fragments
were stained with SYBR SafeTM (Invitrogen1, Carlsbad, CA,
USA) and visualized by UV illumination. PCR amplifications
were compared with both positive and negative controls.
Molecular weight marker (Ladder 100, Invitrogen) was added
in each set.
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GCF samples were obtained from the same periodontal sites
selected for microbial sampling. One strip of perio-paper
(PerioCol Collection Strip, Oraflow, Plainview, NY, USA) was
inserted into the gingival crevice/periodontal pocket and
removed after 30 s. The volume of the fluid was determined
using a moisture metre (Periotron 6000, IDE Interstate,
Amityville, NY, USA). After that, all perio-paper strips were
placed in tubes containing 500 mL of sterile 0.01 M sodium
phosphate buffer, pH 7.4, and vortex mixed for 30 s. Samples
were then centrifuged for 10 min at 6000  g, and supernatant
was collected and stored at 80 8C. The cell pellet was stored in
RNA stabilization solution (Trizol, Invitrogen, Carlsbad, CA,
USA) at 80 8C.
2.6. TNF-a levels in the GCF
Tumour necrosis factor-a levels were determined by using
commercially available enzyme-linked immunosorbant
assays (R&D Systems, Minneapolis, MN, USA). The concentra-
tion of the inflammatory mediators was calculated using the
Softmax data analysis program (Molecular Devices, Menlo
Park, CA, USA).
2.7. PAR2 gene expression by reverse-transcription PCR
(RT-PCR)
Total RNA was isolated from the cell pellet of the GCF by the
single-step method, using phenol and chloroform/isoamylal-
cohol. RNA was reverse-transcribed into cDNA by using the
ready-to-go RT-PCR beads kit (Amersham Biosciences, Buck-
inghamshire, UK). Briefly, 2 mg of total RNA was used and the
reaction included the random primer p(dN)6. After reverse
transcription according to manufacturers’ instructions, PCR
amplification was performed with the addition of specific
primers. For PAR2, upstream: 50-TGGGTTTGCCAAGTAACGGC-
30, and downstream: 50-GGGAGATGCCAATGGCAATG-30. For
GAPDH, upstream: 50-TGGTATCGTGGAAGGACTCATGAC-30,
and downstream, ATGCCAGTGAGCTTCCCGTTCAGC-30. PCR
products were loaded in 1.5% agarose gel and, 26 mL of PAR2 or
GAPDH PCR products were loaded for each sample. The sizes
of the amplified fragments were 324 bp and 189 bp for PAR2
and GAPDH, respectively. Amplified samples were visualized
under UV light after being stained with SYBR SafeTM
(Invitrogen1, Carlsbad, CA, USA). Results are expressed as
PAR2 to GAPDH ratios.Table 1 – Clinical parameters.
PD (mm) SD CAL
Control N = 10 1.02 0.21 0.9
Chronic periodontitis (CP) N = 10 3.22a 0.55 2.3
CP post-treatment (CPT) N = 10 2.4a,b 0.36 2.0
N: number of subjects; SD: standard deviation; PD: mean probing depth
index. Number of sites > 4 mm on CP-group: 493 of 1326, i.e., about 37%
a Statistically different compared to control group, p < 0.05.
b Statistically different compared to CP group, p < 0.05.2.8. Saliva sampling
Saliva samples were collected from all individuals. Samples
taken from subjects in the control group were collected at
baseline, whereas individuals in the chronic periodontitis
group were subjected to two saliva sample collections, one
at baseline, previous to periodontal therapy, and the other
fifty days after comprehensive periodontal therapy. During
the procedure, subjects were instructed to rinse their mouth
with water and chew a piece of sterilized rubber tourniquet
to stimulate saliva, which was collected to yield a total
1.0 mL. Samples were centrifuged for 10 min at 15,000  g at
4 8C, and the supernatants were immediately stored
at 80 8C.
2.9. ELISA for human b-defensin 2 (HBD-2)
The quantification of HBD-2 in saliva was done by an Enzyme
Linked Immunosorbent Assay – ELISA (Peprotech, Rocky Hill,
NJ, USA) according to manufacturer’s instructions. The
process was carried as follows: 100 mL (0.25 mg/mL) of specific
antibody (anti-HBD-2) was added to the 96-well polystyrene
ELISA plates and incubated overnight (4 8C); after being
washed four times with PBST (PBS with 0.05% Tween-20),
300 mL of a blocking solution (1% BSA in PBST) was added to the
wells and incubated for 1 h at room temperature. Plates were
then washed and 100 mL of the samples or standards were
added into the respective wells in duplicate and these plates
were incubated for 2 h. After washing, 100 mL of detection
antibody (0.5 mg/mL) was applied to the wells and plates were
incubated for 2 h. After this period, plates were washed and
100 mL of streptavidin-conjugated horseradish peroxidase
(1:2000 in PBST) was added to the respective wells and
incubated for 30 min. Colorimetric reactions were developed
using o-phenylenediamine in the presence of 0.02% H2O2.
Reaction was stopped using H2SO4 (2N) and measured by an
ELISA reader (OD 490 nm).
2.10. Statistical analysis
One-way analysis of variance was used to compare means
among groups. In case of significant differences among
groups, post hoc two-group comparisons were assessed with
a Tukey–Kramer test. The prevalence of P. gingivalis among
groups was analysed using the chi-square test. A p
value < 0.05 was considered statistically significant. Data are
expressed as mean  SE. (mm) SD PI (%) SD GI (%) SD
5 0.4 38.11 11.9 18.46 9.32
2a 1 78.8a 19.31 72.5a 18.68
3a,b 1.26 22.2a,b 13.13 23.5a,b 11.19
; CAL: mean clinical attachment level; PI: plaque index; GI: gingival
 of overall.
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3.1. Clinical findings
Mean pocket depth (PD) and mean clinical attachment loss
(CAL) were significantly higher ( p < 0.05) in subjects in the
chronic periodontitis group than in those in control. Clinical
parameters were significantly ( p < 0.05) improved by conven-
tional periodontal treatment (Table 1).
3.2. Laboratory findings
Patients with chronic periodontitis showed a significant
increase ( p < 0.001) in the mean PAR2 mRNA expression
relative to the GAPDH RT-PCR signal. Moreover, conventional
periodontal treatment significantly ( p < 0.05) decreased PAR2
mRNA expression (Fig. 1A).
Although being significantly ( p < 0.05) more prevalent in
patients with chronic periodontitis than in those in the controlFig. 1 – (A) Detection of PAR2 in human GCF by RT-PCR.
mean W SEM mRNA ratio PAR2/GAPDH for control, chronic
periodontitis patients at baseline (CP), and after
periodontal therapy (CPT) groups; significant difference
(*p < 0.05) versus control group; N = 10 subjects per group;
(B) percentage of prevalence of Porphyromonas gingivalis
(Pg) in control, chronic periodontitis patients at baseline
(CP), and after periodontal therapy (CPT) groups;
significant difference (*p < 0.05) versus prevalence of
Porphyromonas gingivalis (Pg) at control group; significant
difference (**p < 0.05) versus prevalence of Porphyromonas
gingivalis (Pg) at baseline; N = 10 subjects per group.
Fig. 2 – (A) Levels of the pro-inflammatory mediator TNF-a
(mean W SEM) in the GCF of control, chronic periodontitis
at baseline (CP), and after periodontal therapy (CPT)
groups; N = 10 subjects per group; significant difference
(*p < 0.05) versus control group; significant difference
(**p < 0.05) versus baseline; (B) levels of HBD-2
(mean W SEM) in the saliva of control, chronic periodontitis
at baseline (CP), and after periodontal therapy (CPT)
groups; N = 10 subjects per group; significant difference
(*p < 0.05) versus control group; significant difference
(**p < 0.05) versus baseline.group, the levels of P. gingivalis decreased after periodontal
therapy ( p < 0.0001) (Fig. 1B).
Levels of TNF-a, that were also higher ( p < 0.01) in chronic
periodontitis patients also decreased after periodontal therapy
( p < 0.001) (Fig. 2A).
The same was observed for the mean HBD-2 salivary levels
that were higher in chronic periodontitis subjects than in
controls (Fig. 2B) and that significantly decreased after therapy
( p < 0.05).
4. Discussion
While epithelial tissues from gut, trachea and skin only
express human beta defensin-2 in the presence of infection or
inflammation, the oral epithelium expresses the peptide in
normal healthy gingival tissue.12 HBD-2 expression in normal
oral epithelium is due to the constant stimulation of the innate
immune response by commensal, non-pathogenic bacteria.13
In the normal gingival tissue, peptides are detected in the
upper spinous, granular, and cornified layers, while mRNA is
more strongly expressed in the spinous layer of the tissue. In
the presence of pathogenic bacteria, upregulation of HBD-2
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biofilm in the inflamed epithelium.12
The nature of the epithelial cell receptors which are able to
detect microorganisms and induce the production of the
antimicrobial peptides is still not well known. Although we
already understand that toll-like receptors 2 and 4 can
recognize gram positive and gram negative bacteria resulting
in the activation of transcriptional factors that mediate several
innate and inflammatory responses,14,15 there has not been
any convincing evidence of their involvement in the regula-
tion of HBD-2 in oral epithelial cells.16
Protease-activated receptor (PAR) is another family of
membrane receptors17 that probably play a role in the
inflammatory and host defence response to pathogenic
bacteria, including the modulation of human b defensins.18
PAR may be activated in the oral cavity through its proteolytic
cleavage by P. gingivalis bacterial proteases.19 Our results
demonstrated that, when compared to periodontally healthy
individuals, chronic periodontitis patients show statistically
significant higher levels of HBD-2 and an upregulation of PAR2.
Besides, we also observed that periodontal treatment signifi-
cantly reduced PAR2 expression and human b defensin-2
levels in chronic periodontitis patients ( p < 0.001).
We have previously demonstrated that in subjects with
chronic periodontitis a higher expression of PAR2 in the
gingival crevicular fluid was associated with higher levels of
pro-inflammatory mediators, total proteolytic activity, P.
gingivalis prevalence and neutrophil-protease 3 mRNA expres-
sion.10 Another study by our group showed that the presence
of P. gingivalis in the periodontal pocket of chronic periodonti-
tis patients is associated with higher proteolytic activity, and a
marked increased expression of PAR2.
11 These evidences
suggest that PAR2 plays an important role in the pathogenesis
of periodontal disease in response to proteases secreted by P.
gingivalis.
Chung et al.7 demonstrated that bacterial proteases such as
gingipains from P. gingivalis induced expression of human b
defensins in human gingival epithelial cells by activating PAR2.
Furthermore, Barrera et al.20 showed that proteolytic antibodies
present in the human milk may activate PAR2, which in turn
induces HBD-2 expression. The exact mechanism(s) by which
PAR2 is associated with an increase in HBD-2 levels remains to
be established in further studies. A recent study by Lee et al.21
showed that PAR2 activation by proteases secreted by Propio-
nibacterium acnes leads to both TNF-a and HBD-2 mRNA
expression in acne lesions. Accordingly, Shin and Choi22
showed that Treponema denticola suppresses the expression of
HBD-2 in gingival epithelial cells by inhibiting TNF-a produc-
tion. Interestingly, in the present study, increased prevalence of
P. gingivalis and levels of TNF-a were associated with higher
salivary levels of HBD-2 in chronic periodontitis. In addition,
periodontal treatment resulted in lower levels of both TNF-
alpha and human b-defensin associated with a decreased
prevalence of P. gingivalis. These evidences suggest the
hypothesis that PAR2 activation by gingipains mediates the
increased production of TNF-a, therefore leading to increased
human b expression in chronic periodontitis.
Several studies have demonstrated that elevated levels
of human b defensins are present in saliva and periodontal
tissues of patients with gingivitis, periodontitis, andperi-implantitis.1–5 This is, as far as we know, the first study
to show that after periodontal treatment the salivary levels of
HBD-2 are decreased and associated with a decreased
expression of PAR2. The exact role of PAR2 on human
periodontal inflammation is still not clearly defined; howev-
er, it seems likely that it might play an important role in
innate immune defence during periodontal disease by
leading to the production of anti-bacterial peptides and
pro-inflammatory mediators.
In conclusion, Our results suggest that salivary HBD-2
levels and PAR2 mRNA expression from GCF are higher in
subjects with chronic periodontitis than in healthy subjects,
and that periodontal treatment decreases both HBD-2 levels
and PAR2 expression. Thus, anti-bacterial peptides prodution
might be an important role played by PAR2 in innate immune
defence during periodontal disease.
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